CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
Hadas Lewinsky(Weizmann Institute of Science), Idit Shachar(Weizmann Institute of Science), Steven T. Rosen(Unknown), Enrico Caserta(City of Hope), Keren David(Weizmann Institute of Science), Shirly Becker-Herman(Weizmann Institute of Science), Estelle Troadec(City of Hope), Michael Rosenzweig(Boston University), Matthias P. Kramer(Weizmann Institute of Science), Bianca Pellegrino(Weizmann Institute of Science), Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jianhua Yu(University of California, Irvine), Yosef Cohen(Presbyterian Medical Center), Michal Perpinial(Weizmann Institute of Science), Peter P. Lee(City Of Hope National Medical Center), Jonathan J. Keats(Translational Genomics Research Institute), Olga Shevetz, Emine Gulsen Gunes(City Of Hope National Medical Center), Ting-Fang He, Lihi Radomir(Weizmann Institute of Science), Jing Chen, Kun‐Yu Teng, S. Bhattacharya(Institute of Nuclear Physics, Polish Academy of Sciences), Flavia Pichiorri(City Of Hope National Medical Center), Mingye Feng(City Of Hope National Medical Center), Amrita Krishnan(City of Hope), Anthony G. Mansour(City Of Hope National Medical Center)
Cited by 6
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
|Blood|2018|492
Enabling Technologies for Personalized and Precision Medicine
|Trends in biotechnology|2020|483